Design Weave Future Textiles Outlast Regu Temperature All Charlotte Mall Season $136 Design Weave Future Textiles Outlast All Season Temperature Regu Home Kitchen Bedding Mattress Pads Toppers Design Weave Future Textiles Outlast Regu Temperature All Charlotte Mall Season Outlast,$136,Weave,Home Kitchen , Bedding , Mattress Pads Toppers,Season,Temperature,Design,All,adw.cl,Future,Regu,Textiles,/kersey585577.html Outlast,$136,Weave,Home Kitchen , Bedding , Mattress Pads Toppers,Season,Temperature,Design,All,adw.cl,Future,Regu,Textiles,/kersey585577.html $136 Design Weave Future Textiles Outlast All Season Temperature Regu Home Kitchen Bedding Mattress Pads Toppers

Design Weave wholesale Future Textiles Outlast Regu Temperature All Charlotte Mall Season

Design Weave Future Textiles Outlast All Season Temperature Regu

$136

Design Weave Future Textiles Outlast All Season Temperature Regu

|||

Product description

Size:King

It’s not too hot. It’s not too cold... It’s just right. Outlast technology, originally developed for NASA, utilizes change phase materials (PCM) that absorb, store and release heat for optimal thermal comfort. Outlast technology buffers against temperature fluctuations, helping to keep your personal microclimate steady and comfortable. Outlast technology doesn’t just wick moisture away from the body—it helps to proactively manage sweat before it begins. When you overheat, your body naturally releases excess heat and sweats to cool the skin. Outlast helps alleviate these spikes in skin temperature that cause sleep disturbances by absorbing and storing the excess heat. As you cool, the stored heat is released back to the body for optimal thermal comfort. This cycle continues throughout the night, so you wake up feeling more refreshed and rested. More than just temperature regulating. With a super-soft sateen weave, this mattress pad will keep your bed comfortable and luxurious. The tight-knit weave also repels traditional allergens such as dust mites, which can disrupt sensitive sleepers. Get that cool, crisp, off-the-line freshness every single night. Order your Outlast Temperature Regulating Mattress Pad today!


From the manufacturer

"tbody" "th" Outlast Blankets "th" Outlast Comforters "th" Librium Mattress Pads "th" Outlast Sheets "th" Outlast Pillows "th" Outlast Duvet Comforter Covers
cobija, lecho, ropa de cama, sabanas, individual, matrimonial, matrimonio extra grande, single cobija, lecho, ropa de cama, sabanas, individual, matrimonial, matrimonio extra grande, single cobija, lecho, ropa de cama, sabanas, individual, matrimonial, matrimonio extra grande, single cobija, lecho, ropa de cama, sabanas, individual, matrimonial, matrimonio extra grande, single cobija, lecho, ropa de cama, sabanas, individual, matrimonial, matrimonio extra grande, single cobija, lecho, ropa de cama, sabanas, individual, matrimonial, matrimonio extra grande, single
Sizes Twin, Full, Queen and King Twin, Full, Queen and King Twin, Twin-XL, Full, Queen, King and California King Twin, Twin-XL, Full, Queen, King and California King Standard / Queen and King Queen and King
Colors White, Midnight Blue, Linen and Stone Gray White White Yellow, Green, Lake Blue, Linen, Midnight Blue, Rose Pink, Stone Gray and White White White, Midnight Blue, Linen and Stone Gray
Thread Count 300 300 250 300 350 300
Material 100% Cotton Sateen Weave 100% Cotton Sateen Weave 100% Cotton Sateen Weave 60% Cotton Sateen Weave, 40% Outlast 100% Cotton Sateen Weave 60% Cotton Sateen Weave, 40% Outlast
Fill 50% Outlast, 50% Polyester Fiber Fill 50% Outlast, 50% Polyester Fiber Fill 100% Polyester Fiber Fill with Outlast Liner 100% Polyester Fiber Fill with Outlast Liner
"div"

Design Weave Future Textiles Outlast All Season Temperature Regu

CURRENT ISSUE
September, 2021

No. 106 (9)

2020 Impact Factor: 9.941 Submission > Acceptance: 52 days
ARTICLES IN THREE SENTENCES
Article

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

This open-label, single-arm study investigated the long-term efficacy of tafasitamab plus lenalidomide in 81 patients with relapsed/refractory diffuse large B-cell lymphoma. The response rate was 57.5%, including complete responses in 40.0% of patients, and the median duration of response was 43.9 months. This treatment is a valuable option for patients not eligible for autologous stem-cell transplantation.

Johannes Duell et al.

Case Report

Clinical genomic profiling of novel grey zone lymphoma paired lesions with sequential central nervous system involvement in two adolescent patients

Grey zone lymphoma is a B-cell lymphoma, unclassifiable, with features intermediate between those of large B-cell lymphoma and classic Hodgkin lymphoma. The in-depth study of the two adolescent patients described in this case report expands the clinicopathological and genomic spectrum of this rare pediatric disease. Moreover, it provides information on their response to treatment.

Cagla Y. Benkli et al.

Article

CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients

The clinical picture of 56 patients with congenital amegakaryocytic thrombocytopenia due to MPL mutations was much more varied than previously thought. Twenty-five per cent of them had no signs of thrombocytopenia at birth, and 50% had non-hematologic defects. Pancytopenia developed in (nearly) all patients and hematopoietic stem-cell transplantation was effective in 87% of cases.

Manuela Germeshausen et al.

Article

Oxidative stress activates red cell adhesion to laminin in sickle cell disease

Sickle red blood cells exhibit abnormal adhesion to laminin mediated by Lu/BCAM protein at their surface. This study provides evidence of the involvement of oxidative stress in post-translational modifications of Lu/BCAM which impact the protein’s distribution and cis-interaction with glycophorin C at the cell surface activating its adhesive function in dense sickle red cells. The authors speculate that antioxidant drugs might attenuate this phenomenon.

Maria Alejandra Lizarralde-Iragorri et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA